To evaluate whether rPR8-CCL19 could activate systemic anti-tumor immunity, mice spleen cells were prepared for flow cytometry to detect the cell phenotypes and confirm the differentiation and development of immune cells after treatment. This evidence concerns the gene CCL19 and neoplasm.